More meticulously following treat-to-target in RA does not lead to less radiographic progression: A longitudinal analysis in BIODAM

Sofia Ramiro; Robert Landewé; Désirée van der Heijde; Alexandre Sepriano; Oliver FitzGerald; Mikkel Østergaard; Joanne Homik; Ori Elkayam; J Carter Thorne; Maggie J Larché; Gianfranco Ferraccioli; Marina Backhaus; Gilles Boire; Bernard Combe; Thierry Schaeverbeke; Alain Saraux; Maxime Dougados; Maurizio Rossini; Marcello Govoni; Luigi Sinigaglia; Alain G Cantagrel; Cornelia F Allaart; Cheryl Barnabe; Clifton O Bingham; Dirkjan van Schaardenburg; Hilde B Hammer; Rana Dadashova; Edna Hutchings; Joel Paschke; Walter P Maksymowych

More meticulously following treat-to-target in RA does not lead to less radiographic progression: A longitudinal analysis in BIODAM

Sofia Ramiro^*, Robert Landewé, Désirée van der Heijde, Alexandre Sepriano, Oliver FitzGerald, Mikkel Østergaard, Joanne Homik, Ori Elkayam, J Carter Thorne, Maggie J Larché, Gianfranco Ferraccioli, Marina Backhaus, Gilles Boire, Bernard Combe, Thierry Schaeverbeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi SinigagliaAlain G Cantagrel, Cornelia F Allaart, Cheryl Barnabe, Clifton O Bingham, Dirkjan van Schaardenburg, Hilde B Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P Maksymowych

^*Corresponding author af dette arbejde

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

Abstract

Background/Purpose:

A Treat-to-Target approach (T2T) is broadly considered to lead to better clinical outcomes and recommended in patients with RA. However, very few studies have analyzed the effect of T2T on radiographic progression, and any such studies have provided inconsistent results. Our aim was to investigate whether meticulously following a treat-to-target (T2T)-strategy in daily clinical practice leads to lower radiographic progression in RA

Originalsprog	Engelsk
Publikationsdato	2022
Status	Udgivet - 2022
Begivenhed	ACR 2022 - Philadelphia Varighed: 10 nov. 2022 → 14 nov. 2022

Konference

Konference	ACR 2022
By	Philadelphia
Periode	10/11/2022 → 14/11/2022

Citationsformater

Ramiro, S., Landewé, R., van der Heijde, D., Sepriano, A., FitzGerald, O., Østergaard, M., Homik, J., Elkayam, O., Thorne, J. C., Larché, M. J., Ferraccioli, G., Backhaus, M., Boire, G., Combe, B., Schaeverbeke, T., Saraux, A., Dougados, M., Rossini, M., Govoni, M., ... Maksymowych, W. P. (2022). More meticulously following treat-to-target in RA does not lead to less radiographic progression: A longitudinal analysis in BIODAM. Arthritis & Reumatology Vol. 74, number S9, p. 3965. Abstract fra ACR 2022, Philadelphia.

More meticulously following treat-to-target in RA does not lead to less radiographic progression: A longitudinal analysis in BIODAM. / Ramiro, Sofia; Landewé, Robert; van der Heijde, Désirée et al.
2022. Arthritis & Reumatology Vol. 74, number S9, p. 3965 Abstract fra ACR 2022, Philadelphia.

Publikation: Konferencebidrag › Konferenceabstrakt til konference › Forskning › peer review

Ramiro, S, Landewé, R, van der Heijde, D, Sepriano, A, FitzGerald, O, Østergaard, M, Homik, J, Elkayam, O, Thorne, JC, Larché, MJ, Ferraccioli, G, Backhaus, M, Boire, G, Combe, B, Schaeverbeke, T, Saraux, A, Dougados, M, Rossini, M, Govoni, M, Sinigaglia, L, Cantagrel, AG, Allaart, CF, Barnabe, C, Bingham, CO, van Schaardenburg, D, Hammer, HB, Dadashova, R, Hutchings, E, Paschke, J & Maksymowych, WP 2022, 'More meticulously following treat-to-target in RA does not lead to less radiographic progression: A longitudinal analysis in BIODAM', ACR 2022, Philadelphia, 10/11/2022 - 14/11/2022 s. Arthritis & Reumatology Vol. 74, number S9, p. 3965.

@conference{2a0a9a69037f4e5cb8a8aa2cb6d0f4ac,

title = "More meticulously following treat-to-target in RA does not lead to less radiographic progression: A longitudinal analysis in BIODAM",

abstract = "Background/Purpose: A Treat-to-Target approach (T2T) is broadly considered to lead to better clinical outcomes and recommended in patients with RA. However, very few studies have analyzed the effect of T2T on radiographic progression, and any such studies have provided inconsistent results. Our aim was to investigate whether meticulously following a treat-to-target (T2T)-strategy in daily clinical practice leads to lower radiographic progression in RA",

keywords = "Antirheumatic Agents/therapeutic use, Arthritis, Rheumatoid/diagnostic imaging, Disease Progression, Female, Humans, Male, Middle Aged, Remission Induction, Severity of Illness Index, treat-to-target, radiographic progression, RA, outcomes",

author = "Sofia Ramiro and Robert Landew{\'e} and {van der Heijde}, D{\'e}sir{\'e}e and Alexandre Sepriano and Oliver FitzGerald and Mikkel {\O}stergaard and Joanne Homik and Ori Elkayam and Thorne, {J Carter} and Larch{\'e}, {Maggie J} and Gianfranco Ferraccioli and Marina Backhaus and Gilles Boire and Bernard Combe and Thierry Schaeverbeke and Alain Saraux and Maxime Dougados and Maurizio Rossini and Marcello Govoni and Luigi Sinigaglia and Cantagrel, {Alain G} and Allaart, {Cornelia F} and Cheryl Barnabe and Bingham, {Clifton O} and {van Schaardenburg}, Dirkjan and Hammer, {Hilde B} and Rana Dadashova and Edna Hutchings and Joel Paschke and Maksymowych, {Walter P}",

note = "COPECARE; ACR 2022 ; Conference date: 10-11-2022 Through 14-11-2022",

year = "2022",

language = "English",

pages = "Arthritis & Reumatology Vol. 74, number S9, p. 3965",

}

TY - ABST

T1 - More meticulously following treat-to-target in RA does not lead to less radiographic progression: A longitudinal analysis in BIODAM

AU - Ramiro, Sofia

AU - Landewé, Robert

AU - van der Heijde, Désirée

AU - Sepriano, Alexandre

AU - FitzGerald, Oliver

AU - Østergaard, Mikkel

AU - Homik, Joanne

AU - Elkayam, Ori

AU - Thorne, J Carter

AU - Larché, Maggie J

AU - Ferraccioli, Gianfranco

AU - Backhaus, Marina

AU - Boire, Gilles

AU - Combe, Bernard

AU - Schaeverbeke, Thierry

AU - Saraux, Alain

AU - Dougados, Maxime

AU - Rossini, Maurizio

AU - Govoni, Marcello

AU - Sinigaglia, Luigi

AU - Cantagrel, Alain G

AU - Allaart, Cornelia F

AU - Barnabe, Cheryl

AU - Bingham, Clifton O

AU - van Schaardenburg, Dirkjan

AU - Hammer, Hilde B

AU - Dadashova, Rana

AU - Hutchings, Edna

AU - Paschke, Joel

AU - Maksymowych, Walter P

N1 - COPECARE

PY - 2022

Y1 - 2022

N2 - Background/Purpose: A Treat-to-Target approach (T2T) is broadly considered to lead to better clinical outcomes and recommended in patients with RA. However, very few studies have analyzed the effect of T2T on radiographic progression, and any such studies have provided inconsistent results. Our aim was to investigate whether meticulously following a treat-to-target (T2T)-strategy in daily clinical practice leads to lower radiographic progression in RA

AB - Background/Purpose: A Treat-to-Target approach (T2T) is broadly considered to lead to better clinical outcomes and recommended in patients with RA. However, very few studies have analyzed the effect of T2T on radiographic progression, and any such studies have provided inconsistent results. Our aim was to investigate whether meticulously following a treat-to-target (T2T)-strategy in daily clinical practice leads to lower radiographic progression in RA

KW - Antirheumatic Agents/therapeutic use

KW - Arthritis, Rheumatoid/diagnostic imaging

KW - Disease Progression

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Remission Induction

KW - Severity of Illness Index

KW - treat-to-target

KW - radiographic progression

KW - RA

KW - outcomes

M3 - Conference abstract for conference

SP - Arthritis & Reumatology Vol. 74, number S9, p. 3965

T2 - ACR 2022

Y2 - 10 November 2022 through 14 November 2022

ER -

More meticulously following treat-to-target in RA does not lead to less radiographic progression: A longitudinal analysis in BIODAM

Abstract

Konference

Fingeraftryk

Citationsformater